Cantargia is a startup based in Sweden, most recent round Series B, 1 tracked investor.
Cantargia is a company founded in 2009 headquartered in Sweden. Its most recent tracked round is Series B. Brouky records 1 investor associated with the company.
Cantargia is a biotechnology company focused on developing antibody-based treatments for cancer and inflammatory/autoimmune diseases, primarily targeting the IL1RAP protein. Its lead candidate, nadunolimab, is in clinical trials for pancreatic cancer and other solid tumors, while a second candidate, CAN10, addresses autoimmune conditions.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.